Sanofi’s Patents on Cancer Drug Taxotere Invalidated
This article is for subscribers only.
Sanofi’s two patents on the cancer drug Taxotere were ruled invalid and unenforceable by a U.S. court today in a victory for generic-drug makers Hospira Inc. and Apotex Inc.
The U.S. Court of Appeals for the Federal Circuit upheld a lower court finding on the two patents. The decision was posted on the court’s website.